Investment, Funding & Disinvestments

This initiative directly supports Oman Vision 2040, the national strategic framework that prioritizes industrial diversification and self-sufficiency in essential sectors.

As part of AAIB’s corporate social responsibility efforts, the system draws on cutting-edge global oncology technology.

The facility will occupy a 23,250-square-meter site in Sudair Industrial City, a planned development located 93 miles northwest of Riyadh.

The new facility will generate approximately 500 permanent biomanufacturing positions once operational.

Scinai will retain the plant’s entire workforce as it integrates the facility into its CDMO operations.

AbbVie plans to hire 300 new employees for the facilities, targeting engineers, scientists, manufacturing operators, and lab technicians in the North Chicago area.

Novartis will continue operating its subsidiary Novartis Healthcare Private Limited, which serves as the commercial arm for the company’s operations in India.

The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.

These investments aim to elevate the standard of care available to patients while positioning Alameda as a provider of choice for complex medical procedures.

At the heart of this collaboration sits Ribo’s GalSTAR platform, a specialized system designed to help develop RNA interference therapeutics that target disease-causing genes in liver conditions.